EGFR and cancer: Immunohistochemical staining of the excised transplanted tumours (Fig. 7) further validated that similarity to the lapatinib treatment group; C2 effectively inhibited the expression of Ki-67, phosphor-EGFR, CD49f and CD133 in cancer cells in a dose-dependent manner, while CDDP failed to exert such inhibitory effects.